Investors
Transforming drug manufacturing
rBIO has developed a proprietary bacteria-based peptide manufacturing process that increases production output and improves the economics of essential peptide drugs.
Corporate profile
rBIO is an early-stage biotechnology company focused on developing a platform to address the economics and access to essential peptide drugs. We are transforming peptide drug manufacturing.
The company is focused first on insulin, with a licensing-first model for qualified regional and strategic partners.
rBIO in a nutshell:
- Peptide manufacturing platform
- Proprietary process that increases output
- Licensing model for regional and global partners
- Experienced leadership and investor-aligned commercialization plan
Business model
The company has developed a proprietary manufacturing process that increases output, lowers the cost of peptide production, and creates a repeatable licensing model for multiple peptides.
The problem we address:
Essential peptide drugs including insulin, with complex manufacturing practice, margin pressure and supply vulnerability continues to drive up cost.
For manufacturers and regional partners, a more efficient insulin production process improves commercial economics while supporting broader access.
Investor relevance
- Large essential peptide drug market
- Persistent manufacturing inefficiency
- Supply pressure as major manufacturers shift focus
- Need for qualified regional production capacity
- Potential for licensing-driven scale
rBIO’s platform doubles the rate of insulin production compared with current industry production.
What rBIO has built
- Proprietary insulin manufacturing process
- Process IP and technical know-how
- Bacteria-based production approach
- Scale-up path from 20L pilot work to 1,000L production
- Licensing model for qualified manufacturing partners
Our secret sauce
Technical differentiation
What makes rBIO different.
The platform combines a bacteria-based production system, proprietary operating knowledge and a transfer-ready licensing model designed to improve manufacturing and partner economics.
| Differentiator | What it means | Investor relevance |
|---|---|---|
| Bacteria-based production | A bacterial production process rather than more complex conventional methods. | Simplifies production economics and supports higher output. |
| Proprietary process know-how | Process design, manufacturing learning, scale-up methods and operating knowledge. | Creates a defensible operating advantage. |
| Increased output | Greater insulin production output compared with current industry methods. | Improves manufacturing and licensee economics. |
| Scale-up path | Progression from completed 20L pilot work toward the 1,000L milestone. | Provides a defined technical milestone toward licensing. |
| Licensing-ready model | Process transfer to qualified manufacturing partners in priority markets. | Supports capital-efficient commercialization. |
| Peptide expansion | Insulin is the first application, with additional peptide potential. | Extends platform value beyond the first license. |
World-class team
Scientific, operational, financial and investor experience.
CEO / Co-founder
Dr. Deen Bakthavatsalam
More than two decades building and commercializing biotechnology innovations across product development, manufacturing and strategic partnerships.
Executive Chairman
Stuart Douglass
Life-sciences investor and company builder providing strategic guidance, governance and long-term shareholder perspective.
CFO
Shawn Swaney
Financial strategy, fundraising, investor relations and disciplined capital planning for high-growth companies.
Board Member
Dr. Judith Shizuru
Stanford physician, biotechnology founder, entrepreneur and investor with company-building and fundraising experience.
Co-founder
Cameron Owen
Entrepreneurial vision, strategic partnerships, business development and commercial deal-making.
Market opportunity
Large licensing opportunity, insulin-first entry point.
The company licenses insulin first, expands by geography and partner category, then extends the platform to additional peptide drugs.
A letter of intent is in place for the first insulin licensing deal.
$250B*
Global licensing market referenced in current investor materials.
Competitive position
Focused where manufacturing economics and licensing meet.
Unlike broad service providers or generalized peptide-platform startups, rBIO combines an insulin focus, licensing model, process know-how and expansion potential.
| Company type | Insulin focus | Licensing model | Know-how | Multiple peptides |
|---|---|---|---|---|
| rBIO | High | High | High | High |
| Contract research organizations | Low | Service-led | Moderate | High |
| General peptide startups | Low | Emerging | Varies | Emerging |
Customer and licensee targets
Qualified partners with a reason to improve production economics.
rBIO evaluates potential licensees by insulin focus, licensing receptivity, need for process know-how, manufacturing capability, market access and margin pressure.
| Customer type | Insulin fit | Licensing fit | Need for know-how | Margin-pressure fit |
|---|---|---|---|---|
| Biosimilar players | Strong | Strong | Lower | Strong |
| Traditional pharma | Strong | Lower | Moderate | Moderate |
| CDMOs and contract manufacturers | Lower | Strong | Strong | Strong |
Priority markets with practical licensing paths.
rBIO prioritizes markets where insulin demand, partner availability, manufacturing need, market access and existing relationships support commercialization.
Mexico and Latin America
Regional demand, partner access and manufacturing economics create an initial licensing opportunity.
United States and India
Established insulin demand and strategic relationships support selected partnership opportunities.
Middle East and Europe
Regional manufacturers and distributors offer additional paths for insulin and peptide expansion.
Go-to-market strategy
Commercialized through licensing.
rBIO works with qualified manufacturers, CDMOs, distributors, fill-finish owners and strategic pharmaceutical organizations.
Near-term Go-to-Market
- License insulin to drug manufacturers
- Manufacture insulin through India JV
- Sell insulin through regional distribution channels
- Expand into pharma, biotech and specialty peptide markets